Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population

https://doi.org/10.1016/j.amjopharm.2007.05.004Get rights and content

Abstract

Background:

Latanoprost, a prostaglandin inhibitor, is inercasingly being used in the therapcutic management of glaucoma. However, there is scant literature examining the cost and outcome ramifications of latanoprost.

Objectives:

This study examined the medication use behavior (medication-related persistence and adherence rates) and costs associated with the introduction of latanoprost therapy in a treatment-naive older population (aged ≥65 years) enrolled in Medicare.

Methods:

The study employed a retrospective observational cohort design and used administrative claims data from a Medicare health maintenance organization (HMO), which offered complete coverage to enrollees, including prescription benefits. The case group consisted of patients with glaucoma who began latanoprost therapy. The control group consisted of enrollees with glaucoma who started any therapy other than latanoprost. Both groups were followed up for 1 year before and after initiation of therapy. Bivariate and multivariate techniques incorporating health care utilization in the year before the start of new therapy were used to determine the study outcomes.

Results:

The case group comprised 101 patients (mean age, 77.60 years), while the control group included 168 patients (mean age, 77.59 years). There were no significant differences across the 2 groups with respect to age, sex, general health scores on the 12 item Short-Form Health Survey, severity of comorbidity, or the proportion of respondents with perception of worsened health. Introduction of latanoprost therapy was associated with higher medication persistence (hazard ratio, 0.90; 95% CI, 0.68–0.98) and adherence rates (mean [SD], 0.51 [0.26] vs 0.40 [0.25]; P < 0.001) compared with patients starting other glaucoma medication. Furthermore, there were no additional increases in total health care costs in the entire population associated with the introduction of latanoprost therapy, after adjusting for group and time effects, as well as other confounders (mean [SD], $4718.24 [$8982.92] vs $4046.55 [$6505.39]).

Conclusions:

Latanoprost therapy offered improved medication use behavior in these older adults enrolled in a Medicare HMO. There were no significant additional increases in overall health care costs as a result of introduction of latanoprost therapy, after adjusting for group and time effects, as well as other baseline confounders in this study cohort.

References (38)

  • InfeldDA et al.

    Glaucoma: Diagnosis and management

    Postgrad Med J.

    (1998)
  • GordonMO et al.

    The Ocular Hypertension Treatment Study: Design and baseline description of the participants

    Arch Ophthalmol

    (1999)
  • FriedmanDS et al.

    Prevalence of open-angle glaucoma among adults in the United States

    Arch Ophthalmol

    (2004)
  • MarquisRE et al.

    Management of glaucoma: Focus on pharmacological therapy

    Drugs Aging

    (2005)
  • FiscellaRG

    Costs of glaucoma medications

    Am J Health Syst Pharm

    (1998)
  • PoloV et al.

    Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma: A 24-month study

    Ann Ophthalmol

    (2005)
  • Cited by (17)

    • Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results

      2019, Ophthalmology
      Citation Excerpt :

      Although not a study end point, the use of medication before and after stent implantation in the study eye is relevant to the overall characterization of benefit, which is primarily based on the level of IOP reduction achieved after washout. Because patient compliance is known to decrease as the number of medications increases,42-44 and medications have drawbacks such as toxicities and costs,45-47 the proportions of eyes on 0, 1, or ≥2 medications are especially important indicators of treatment utility. In this study, 84% of treatment eyes meeting the primary study end point were not taking ocular hypotensive medications at 23 months, compared with 67% of control eyes.

    • Big data and ophthalmic research

      2016, Survey of Ophthalmology
      Citation Excerpt :

      Nordstom and colleagues found half of patients had discontinued treatment by 6 months and that those taking prostaglandins were 60% less likely to discontinue compared to beta-blockers and carbonic anhydrase inhibitors.193 Other studies using claims data further support the findings from these studies,12,45,95,234,248,284,295,296 including one from Australia using national population-based pharmaceutical claims for 357,099 patients that confirmed superior persistency for prostaglandins.207 Pharmacoepidemiology studies using administrative data have their own unique limitations.228

    • Primary Open-Angle Glaucoma

      2016, Ophthalmology
    • Use of glaucoma medications: State of the science and directions for observational research

      2010, American Journal of Ophthalmology
      Citation Excerpt :

      Supplemental Table 2 provides details of how adherence and persistence were measured in each study. Rates of nonadherence ranged between 23% and 60% over 12 months.24,25,30–33 Rates of nonpersistence ranged between 30% and 95% at 1 year.29,33,39,43–48,50,52

    View all citing articles on Scopus
    View full text